Begimbayeva Gulnara, Botabekova Tursunkul, Yelikbayeva Assel, Voronkova Ekaterina, Kenzhebayeva Kamilla
Department of Ophthalmology, Kazakh-Russian Medical University, 71 Torekulov Str., 050000, Almaty, Republic of Kazakhstan.
Department of Ophthalmology, Ophthalmological Centre "FOCUS", 450 Seifullin Ave., 050000, Almaty, Republic of Kazakhstan.
J Med Microbiol. 2025 Mar;74(3). doi: 10.1099/jmm.0.001978.
Eye diseases are widespread all over the world and, if left untreated, can lead to blindness. The use of 0.05% cyclosporine A (CsA) solution for the treatment of dry eye causes a decrease in discomfort and pain and improves objective measures such as tear film breakdown time, Schirmer test results and Oxford scale scores due to its anti-inflammatory and immunomodulatory properties that contribute to improved tear film stability and tear production. This study aimed to investigate the impact of CsA on the progression of ocular surface diseases. An experiment was conducted on the basis of the FOCUS ophthalmology centre, Kazakhstan. A group of 100 individuals diagnosed with mild to severe dry eye illness were administered 0.05% CsA eye drops as part of the treatment protocol. The positive effect is explained by the anti-inflammatory and immunomodulatory effects of CsA. The study showed that the use of 0.05% CsA solution for the treatment of ocular surface disease led to a decrease in discomfort and pain, as well as an improvement in objective measures, including tear film breakdown time, Schirmer test results and Oxford scale scores. The visual analogue scale showed a significant reduction in symptoms, from 6.8 points at baseline to 3.7 points at day 60. In total, 20% of patients reported moderate side effects, such as pain during instillation and redness of the eye surface. It is concluded that the use of these drops reduced pain, improved patient condition and enhanced indicators such as the visual analogue scale, tear film breakup time, Schirmer test and Oxford scale of corneal and conjunctival staining. This study differs from the previous ones in that it focuses on the efficacy of 0.05% CsA solution in the treatment of dry eye and also examines the spectrum and frequency of side effects, which is not sufficiently covered in previous studies.
眼部疾病在全球广泛存在，若不治疗可导致失明。使用0.05%环孢素A（CsA）溶液治疗干眼症，因其具有抗炎和免疫调节特性，有助于改善泪膜稳定性和泪液分泌，可减轻不适和疼痛，并改善诸如泪膜破裂时间、泪液分泌试验结果及牛津评分等客观指标。本研究旨在探讨CsA对眼表疾病进展的影响。该实验在哈萨克斯坦的FOCUS眼科中心进行。一组100名被诊断为轻至重度干眼症的患者，按照治疗方案使用0.05% CsA滴眼液。其积极效果归因于CsA的抗炎和免疫调节作用。研究表明，使用0.05% CsA溶液治疗眼表疾病可减轻不适和疼痛，同时改善包括泪膜破裂时间、泪液分泌试验结果及牛津评分等客观指标。视觉模拟量表显示症状显著减轻，从基线时的6.8分降至第60天时的3.7分。共有20%的患者报告有中度副作用，如滴药时疼痛和眼表发红。研究得出结论，使用这些滴眼液可减轻疼痛、改善患者状况，并提高视觉模拟量表、泪膜破裂时间、泪液分泌试验以及角膜和结膜染色牛津评分等指标。本研究与以往研究的不同之处在于，它聚焦于0.05% CsA溶液治疗干眼症的疗效，还考察了副作用的范围和发生率，而这在以往研究中并未得到充分涵盖。
